相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
Jacques-Eric Gottenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF THE PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PSUMMIT I STUDY
I. B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Intravenous immunoglobulin and Alzheimer's disease: what now?
David A. Loeffler
JOURNAL OF NEUROINFLAMMATION (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
Sean J. Pittock et al.
LANCET NEUROLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
IBD IN 2012 Pathogenesis and management of IBO-thinking outside the box
Severine Vermeire et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
RENAL VASCULITIS IN 2012 Reclassification and the introduction of biologicals
Cees G. M. Kallenberg
NATURE REVIEWS NEPHROLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Belimumab for Systemic Lupus Erythematosus
Bevra Hannahs Hahn
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab
Iuliana Shapira et al.
ARTHRITIS AND RHEUMATISM (2012)
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
R. D. May et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
J. S. Orange et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2012)
Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review
Dong Xue Wang et al.
CLINICAL RHEUMATOLOGY (2012)
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton et al.
EUROPEAN JOURNAL OF CANCER (2012)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
Socrates Papapoulos et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Gemtuzumab Ozogamicin: Time to Resurrect?
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis
Giorgio Berlot et al.
JOURNAL OF CRITICAL CARE (2012)
Effect of Golimumab on Patient-reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD Study
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
Julien Zuber et al.
NATURE REVIEWS NEPHROLOGY (2012)
Mechanisms of Disease Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Erwin W. Gelfand
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Nicolino Ruperto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Eculizumab in a Patient with Dense-Deposit Disease
Erica Daina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Eculizumab and Refractory Membranoproliferative Glomerulonephritis
Seetha Radhakrishnan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients
S. C. Jordan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients
M. D. Stegall et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2011)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Subcutaneous immunoglobulin in polymyositis and dermatomyositis: A novel application
Maria Giovanna Danieli et al.
AUTOIMMUNITY REVIEWS (2011)
Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
Alessandra Vultaggio et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Use of monoclonal antibodies in renal transplantation
Martijn W. F. van den Hoogen et al.
IMMUNOTHERAPY (2011)
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use
Melvin Berger
IMMUNOTHERAPY (2011)
Current and novel therapeutics in the treatment of systemic lupus erythematosus
Cagri Yildirim-Toruner et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
Sarbjit Saini et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders
Mark Ballow
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study
Isabella Quinti et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis
Marina Morigi et al.
JOURNAL OF IMMUNOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Emerging antibody combinations in oncology
Stephen J. Demarest et al.
MABS (2011)
Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology
Jody D. Berry et al.
NEW BIOTECHNOLOGY (2011)
Antibodies in oncology
Vinochani Pillay et al.
NEW BIOTECHNOLOGY (2011)
Treatment of Neonatal Sepsis with Intravenous Immune Globulin
Peter Brocklehurst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Lebrikizumab Treatment in Adults with Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
Phillip Scheinberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis
Marta Baleva et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
Edward Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
HCV infection in patients with primary defects of immunoglobulin production
I. QUINTI et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
The other side of immunoglobulin G: suppressor of inflammation
S. Aschermann et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies
Jordan S. Orange et al.
CLINICAL IMMUNOLOGY (2010)
Bevacizumab In Previously Treated Glioblastoma
Marit D. Moen
DRUGS (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)
Fereydoun Davatchi et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2010)
Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years
Mary Lucas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
Marc Massanari et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells
Mohan S. Maddur et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Immunoglobulin Dosage and Switch from Intravenous to Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Hypogammaglobulinemia: Decreasing Dosage Does Not Alter Serum IgG Levels
Sylvain Thepot et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
John B. Hagan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Immunomodulatory Therapy to Achieve Maximum Efficacy: Doses, Monitoring, Compliance, and Self-infusion at Home
Mary Lucas et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma
Brian O'Nuallain et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy
Dinesh Khanna et al.
OPHTHALMOLOGY (2010)
Treatment of respiratory syncytial virus with palivizumab: a systematic review
Jia Hu et al.
WORLD JOURNAL OF PEDIATRICS (2010)
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study
Adnan Tufail et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
Alexander Roeth et al.
BLOOD (2009)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
Engineered therapeutic antibodies with improved effector functions
Tsuguo Kubota et al.
CANCER SCIENCE (2009)
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma
M. V. Kopp et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2009)
Intravenous immunoglobulins - understanding properties and mechanisms
A. Durandy et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial
T. Harbo et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Monoclonal antibody-induced cytokine-release syndrome
Peter J. Bugelski et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
Intravenous Immunoglobulin and Anti-RhD Therapy in the Management of Immune Thrombocytopenia
Nichola Cooper
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment
Patrick J. Brennan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Subcutaneous immunoglobulin therapy for multifocal motor neuropathy
Filip Eftimov et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside
G. Zandman-Goddard et al.
LUPUS (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders
H. Fillit et al.
NEUROLOGY (2009)
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Raxibacumab for the Treatment of Inhalational Anthrax.
Thi-Sau Migone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Unlabeled uses of intravenous immune globulin
Hoyee Leong et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients
Anu Jacob et al.
ARCHIVES OF NEUROLOGY (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2008)
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Robert D. Inman et al.
ARTHRITIS AND RHEUMATISM (2008)
Preparation and use of therapeutic antibodies primarily of human origin
E. Richard Stiehm et al.
BIOLOGICALS (2008)
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies
R. Gustafson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Pharmacokinetics of Immunoglobulin Administered via Intravenous or Subcutaneous Routes
Francisco A. Bonilla
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Alessandro D. Santin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2008)
Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection
Vincent R. Bonagura et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Treatment of chronic autoimmune urticaria with omalizumab
Allen P. Kaplan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana K. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
Shumpei Yokota et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Liver transplantation for hepatitis B: What is the best hepatitis B immune globulin/antiviral regimen?
Peter W. Angus et al.
LIVER TRANSPLANTATION (2008)
Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy
De-Hyung Lee et al.
MUSCLE & NERVE (2008)
Therapies for COPD
Uma Yasothan et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Scleromyxedema - A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)
Marissa Blum et al.
MEDICINE (2008)
The antiinflammatory IgG
Srini V. Kaveri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rituximab and intravenous immune globulin for desensitization during renal transplantation
Ashley A. Vo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
Daniel J. Lovell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of a receptor required for the anti-inflammatory activity of IVIG
Robert M. Anthony et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc
Robert M. Anthony et al.
SCIENCE (2008)
Modulation of the cellular immune system by intravenous immunoglobulin
Thanyalak Tha-In et al.
TRENDS IN IMMUNOLOGY (2008)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis
Robert G. W. Lambert et al.
ARTHRITIS AND RHEUMATISM (2007)
Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock
K. Georg Kreyrnann et al.
CRITICAL CARE MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis
Giuseppe Luzi et al.
CLINICAL IMMUNOLOGY (2007)
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death
Thiruma V. Arumugam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy
Kursteen S. Price et al.
ALLERGY AND ASTHMA PROCEEDINGS (2007)
Intravenous immunoglobulin:: An update on the clinical use and mechanisms of action
Vir-Singh Negi et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanism-based model
Jonghan Kim et al.
CLINICAL IMMUNOLOGY (2007)
The antiinflammatory activity of IgG: the intravenous IgG paradox
Falk Nimmerjahn et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Biologic therapies: what and when?
Sarah L. Johnston
JOURNAL OF CLINICAL PATHOLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation
Yoshikatsu Kaneko et al.
SCIENCE (2006)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab for hospitalized patients with severe ulcerative colitis
Miguel Regueiro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2006)
Alemtuzumab (Campath-1H): A systematic review in organ transplantation
Peter J. Morris et al.
TRANSPLANTATION (2006)
Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases
Hans D. Ochs et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2006)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial
A Kastrati et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
JS Orange et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Adverse events associated with intravenous immunoglobulin therapy
DJ Hamrock
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Differences between IGIV products: Impact on clinical outcome
EW Gelfand
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab - Results from the ASPIRE trial
JS Smolen et al.
ARTHRITIS AND RHEUMATISM (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Human botulism immune globulin for the treatment of infant botulism
SS Arnon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis
TB Casale et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy
T Sapir et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2005)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment
S von Gunten et al.
BLOOD (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura
P Brændstrup et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):: INNOVATE
M Humbert et al.
ALLERGY (2005)
Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT)
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Clinical features and severity grading of anaphylaxis
SGA Brown
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Long-term Treatment of Rectovaginal Fistulas in Crohn's Disease: Response to Infliximab in the ACCENT II Study
Bruce E. Sands et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency
P Quartier et al.
CLINICAL IMMUNOLOGY (2004)
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
TF Feltes et al.
JOURNAL OF PEDIATRICS (2003)
Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura
I Hedlund-Treutiger et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2003)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
AA Jungbluth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
The X-linked hyper-IgM syndrome - Clinical and immunologic features of 79 patients
JA Winkelstein et al.
MEDICINE (2003)
Basifiximab - A review of its use as induction therapy in renal transplantation
TM Chapman et al.
DRUGS (2003)
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review
VN van Schaik et al.
LANCET NEUROLOGY (2002)
Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages
S Shapiro et al.
CANCER (2002)
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma
TK Hart et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Multifocal motor neuropathy: Long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment
R. A. Van den Berg-Vos et al.
BRAIN (2002)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2002)
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura:: a randomised, multicentre trial
B Godeau et al.
LANCET (2002)
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
MS Kaminski et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
MD Kazatchkine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Cytokine modulation with immune γ-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment
M Gupta et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Botulinum toxin as a biological weapon - Medical and public health management
SS Arnon et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy
JR Mendell et al.
NEUROLOGY (2001)
Intravenous immunoglobulin therapy in multifocal motor neuropathy - A double-blind, placebo-controlled study
JM Leger et al.
BRAIN (2001)
Multifocal motor neuropathy improved by IVIg - Randomized, double-blind, placebo-controlled study
P Federico et al.
NEUROLOGY (2000)
Passive immunity in prevention and treatment of infectious diseases
MA Keller et al.
CLINICAL MICROBIOLOGY REVIEWS (2000)
Antibodies for the prevention and treatment of viral diseases
LA Sawyer
ANTIVIRAL RESEARCH (2000)
Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis
M Meissner et al.
RHEUMATOLOGY INTERNATIONAL (2000)
Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin
S Ghosh et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
